



MATERIAL SAFETY DATA SHEET

Revision date: 23-Aug-2011

Version: 3.0

Page 1 of 7

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Global Manufacturing
Pfizer Inc
235 East 42nd Street
New York, NY 10017

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Material Name: Epirubicin Hydrochloride Powder for Injection

Trade Name:	Farmorubicin; Pharmorubicin
Synonyms:	Farmorubicin Rapid Dissolution; Farmorubicin RD
Chemical Family:	Anthracycline
Intended Use:	Pharmaceutical product used as Antineoplastic

2. HAZARDS IDENTIFICATION

Appearance: Red freeze-dried powder
Signal Word: WARNING

Statement of Hazard: Suspected of causing cancer.
Suspected of causing genetic defects.

Additional Hazard Information:

Short Term:	Drugs of this class have been associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure.
Long Term:	Repeat-dose studies in animals have shown a potential to cause adverse effects on testes the developing fetus.
Known Clinical Effects:	Adverse effects most commonly reported in clinical use include local irritation, nausea, vomiting, inflammation of the mouth (stomatitis), facial flushing, conjunctivitis of the eye, tearing (lachrymation), loss of hair, and discoloration of skin. Effects on blood and blood-forming organs have also occurred.
EU Indication of danger:	Carcinogenic: Category 2 Mutagenic: Category 2

EU Hazard Symbols:



EU Risk Phrases:

R45 - May cause cancer.
R46 - May cause heritable genetic damage.
Hazardous Substance. Non-Dangerous Goods.

Australian Hazard Classification (NOHSC):

MATERIAL SAFETY DATA SHEET

Material Name: Epirubicin Hydrochloride Powder for Injection
Revision date: 23-Aug-2011

Page 2 of 7
Version: 3.0

2. HAZARDS IDENTIFICATION

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Epirubicin Hydrochloride	56390-09-1	260-145-2	Xn;R22 Repr.Cat.2;R60-61 Muta.Cat.2;R46 Carc.Cat.2;R45	0.2

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Methylparaben	99-76-3	202-785-7	Not Listed	*
Lactose Monohydrate	64044-51-5	Not Listed	Not Listed	*

Additional Information: Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride, and other chlorine-containing compounds.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

MATERIAL SAFETY DATA SHEET

Material Name: Epirubicin Hydrochloride Powder for Injection
Revision date: 23-Aug-2011

Page 3 of 7
Version: 3.0

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions:	Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
Measures for Cleaning / Collecting:	Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.
Measures for Environmental Protections:	Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Additional Consideration for Large Spills:	Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling:	Restrict access to work area. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
Storage Conditions:	Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Epirubicin Hydrochloride Pfizer OEL TWA-8 Hr:	0.6 µg/m ³
--	-----------------------

Analytical Method:	Analytical method available for epirubicin. Contact Pfizer Inc for further information.
Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section. It is recommended that all operations be fully enclosed and no air recirculated.
Environmental Exposure Controls:	Refer to specific Member State legislation for requirements under Community environmental legislation.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious, disposable gloves (double suggested) are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

MATERIAL SAFETY DATA SHEET

Material Name: Epirubicin Hydrochloride Powder for Injection
Revision date: 23-Aug-2011

Page 4 of 7
Version: 3.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Freeze-dried powder	Color:	Red
Molecular Formula:	Mixture	Molecular Weight:	Mixture

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Epirubicin Hydrochloride

Rat	Oral	LD 50	1350 mg/kg
Rat	Para-periosteal	LD50	17 mg/kg
Mouse	Oral	LD50	> 2000 mg/kg
Mouse	Intravenous	LD50	31.5 mg/kg

Lactose Monohydrate

Rat	Oral	LD 50	29700 mg/kg
-----	------	-------	-------------

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Epirubicin Hydrochloride

6 Week(s)	Rabbit	Intravenous	1 mg/kg/day	LOAEL	Heart, Kidney
6 Week(s)	Dog	Intravenous	0.4 mg/kg/day	LOAEL	Kidney

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Epirubicin Hydrochloride

Reproductive & Fertility	Rat	Oral	0.3 mg/kg/day	LOAEL	Fertility
Reproductive & Fertility	Rat	Oral	0.1 mg/kg/day	NOAEL	Fertility
Embryo / Fetal Development	Rat	Intravenous	0.8 mg/kg/day	LOAEL	Fetotoxicity
Embryo / Fetal Development	Rat	Intravenous	2 mg/kg/day	LOAEL	Teratogenic, Fetotoxicity
Embryo / Fetal Development	Rat	Intravenous	0.2 mg/kg/day	NOAEL	Teratogenic, Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Epirubicin Hydrochloride

Bacterial Mutagenicity (Ames)	Positive
Mammalian Cell Mutagenicity	HGPRT Positive

MATERIAL SAFETY DATA SHEET

Material Name: Epirubicin Hydrochloride Powder for Injection
Revision date: 23-Aug-2011

Page 5 of 7
Version: 3.0

11. TOXICOLOGICAL INFORMATION

Chromosome Aberration Human Lymphocytes Positive
Chromosome Aberration Mouse Lymphoma Positive

Lactose Monohydrate

In Vitro Bacterial Mutagenicity (Ames) Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Epirubicin Hydrochloride

1 Year(s) Rat Intravenous 3.6 mg/kg LOAEL Tumors, Female reproductive system
18 Month(s) Rat Intravenous 0.5 mg/kg LOAEL Tumors

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: T
EU Indication of danger: Carcinogenic: Category 2
Mutagenic: Category 2

EU Risk Phrases:

R45 - May cause cancer.
R46 - May cause heritable genetic damage.

EU Safety Phrases:

MATERIAL SAFETY DATA SHEET

Material Name: Epirubicin Hydrochloride Powder for Injection
Revision date: 23-Aug-2011

Page 6 of 7
Version: 3.0

15. REGULATORY INFORMATION

S22 - Do not breathe dust.
S53 - Avoid exposure - obtain special instructions before use.
S36/37 - Wear suitable protective clothing and gloves.

OSHA Label:

WARNING

Suspected of causing cancer.

Suspected of causing genetic defects.

Canada - WHMIS: Classifications

WHMIS hazard class:

D2a very toxic materials



Epirubicin Hydrochloride

EU EINECS/ELINCS List 260-145-2

Methylparaben

Inventory - United States TSCA - Sect. 8(b) Present

Australia (AICS): Present

EU EINECS/ELINCS List 202-785-7

Lactose Monohydrate

Australia (AICS): Present

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.

R45 - May cause cancer.

R46 - May cause heritable genetic damage.

R60 - May impair fertility.

R61 - May cause harm to the unborn child.

Data Sources: Publicly available toxicity information. Pfizer proprietary drug development information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 15 - Regulatory Information.

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

MATERIAL SAFETY DATA SHEET

Material Name: Epirubicin Hydrochloride Powder for Injection
Revision date: 23-Aug-2011

Page 7 of 7
Version: 3.0

End of Safety Data Sheet